Document is current
Any future updates will be listed below
-
Authors
Traore, Karim
Bienvenu, Anne-Lise
Coulibaly, Drissa
Kone, Abdoulaye Kassoum
Zeguime, Amatigue
Bengaly, Karim
Cisse, Mohamed
Tarning, Joel
Thera, Mahamadou Ali
Picot, Stephane
-
Funding
Funding for this research was provided by:
Université Claude Bernard Lyon 1 (Malaria research Unit, UMR 5246)
Université Claude Bernard Lyon 1 (Malaria research Unit, UMR 5246)
Université Claude Bernard Lyon 1 (Malaria research Unit, UMR 246)
Université Claude Bernard Lyon 1 (Malaria research Unit, UMR 5246)
Université Claude Bernard Lyon 1 (Malaria research Unit, UMR 5246)
Wellcome Trust (220211)
Eunovis (BPI France)
- License Information
-
More Information
Article History
Received: 27 January 2026
Accepted: 3 June 2026
First Online: 6 July 2026
Declarations
:
: SP and ALB are shareholders of Eunovis. Eunovis provided a financial support for the preparation of investigational medicinal product.None of the other authors has a competing interest to declare.
: Ethical clearance: The study was conducted in accordance with the Declaration of Helsinki, Good Clinical Practice (GCP), and in accordance with the law n°09–059 of December 28th, 2009, regulating biomedical research on human in Mali. Ethical clearance was obtained from the Ethics comittee of Université des Sciences, des Techniques et des Technologies de Bamako ( USTTB), Faculty of medicine and odonto-stomatology, Point G Bamako 1805 Mali, Approval date: 24/04/2024. The study is registered with Pan-African Clinical Trial Registry (PACTR202408719575384).
